Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1983 1
1985 1
1986 1
1987 4
1988 2
1990 1
1992 2
1993 1
1994 1
1997 1
1998 3
1999 1
2003 1
2004 1
2005 1
2006 1
2015 1
2016 1
2017 1
2018 3
2019 2
2021 2
2022 2
2023 4
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
ALSUntangled #71: Nuedexta.
Sun Y, Benatar M, Mascías Cadavid J, Ennist D, Wicks P, Staats K, Beauchamp M, Jhooty S, Pattee G, Brown A, Bertorini T, Barkhaus P, Bromberg M, Carter G, Bedlack R, Li X. Sun Y, et al. Among authors: ennist d. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb;25(1-2):218-222. doi: 10.1080/21678421.2023.2239292. Epub 2023 Jul 26. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 37493197 Free article. Review.
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Salomon-Zimri S, Pushett A, Russek-Blum N, Van Eijk RPA, Birman N, Abramovich B, Eitan E, Elgrart K, Beaulieu D, Ennist DL, Berry JD, Paganoni S, Shefner JM, Drory VE. Salomon-Zimri S, et al. Among authors: ennist dl. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):263-271. doi: 10.1080/21678421.2022.2119868. Epub 2022 Sep 15. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36106817 Free article. Clinical Trial.
ALSUntangled #70: caffeine.
Hatch J, Barkhaus P, Barnes B, Beauchamp M, Benatar M, Bertorini T, Bowser R, Bromberg M, Brown A, Mascias Cadavid J, Carter GT, Cole N, Crayle J, Dimachkie M, Ennist D, Feldman E, Fullam T, Heiman-Patterson T, Jhooty S, Levine T, Li X, Lund I, Mallon E, Maragakis N, McDermott C, Pattee G, Pierce K, Ratner D, Staats K, Wicks P, Wiedau M, Bedlack R. Hatch J, et al. Among authors: ennist d. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Jun 8:1-5. doi: 10.1080/21678421.2023.2220742. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37288776
ALSUntangled # 69: astaxanthin.
Fullam T, Armon C, Barkhaus P, Barnes B, Beauchamp M, Benatar M, Bertorini T, Bowser R, Bromberg M, Mascias Cadavid J, Carter GT, Dimachkie M, Ennist D, Feldman EL, Heiman-Patterson T, Jhooty S, Lund I, Mcdermott C, Pattee G, Ratner D, Wicks P, Bedlack R. Fullam T, et al. Among authors: ennist d. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):553-557. doi: 10.1080/21678421.2023.2171302. Epub 2023 Jan 24. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36694292 Review.
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.
van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H; Airlie House ALS Clinical Trials Guidelines Group. van den Berg LH, et al. Neurology. 2019 Apr 2;92(14):e1610-e1623. doi: 10.1212/WNL.0000000000007242. Epub 2019 Mar 8. Neurology. 2019. PMID: 30850440 Free PMC article.
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?
Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, Walker J, Sinani E, Katsovskiy I, Cudkowicz M, Leitner ML. Zach N, et al. Among authors: ennist dl. Neurotherapeutics. 2015 Apr;12(2):417-23. doi: 10.1007/s13311-015-0336-z. Neurotherapeutics. 2015. PMID: 25613183 Free PMC article. Review.
Gene therapy for lung disease.
Ennist DL. Ennist DL. Trends Pharmacol Sci. 1999 Jun;20(6):260-6. doi: 10.1016/s0165-6147(99)01350-4. Trends Pharmacol Sci. 1999. PMID: 10366870 Review.
Predicting disease progression in amyotrophic lateral sclerosis.
Taylor AA, Fournier C, Polak M, Wang L, Zach N, Keymer M, Glass JD, Ennist DL; Pooled Resource Open‐Access ALS Clinical Trials Consortium. Taylor AA, et al. Among authors: ennist dl. Ann Clin Transl Neurol. 2016 Sep 7;3(11):866-875. doi: 10.1002/acn3.348. eCollection 2016 Nov. Ann Clin Transl Neurol. 2016. PMID: 27844032 Free PMC article.
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool.
Brooks BR, Pioro EP, Beaulieu D, Taylor AA, Schactman M, Keymer M, Agnese W, Perdrizet J, Apple S, Ennist DL. Brooks BR, et al. Among authors: ennist dl. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Feb;23(1-2):49-57. doi: 10.1080/21678421.2021.1927102. Epub 2021 Jul 10. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 34251911 Free article.
Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis.
Jahandideh S, Taylor AA, Beaulieu D, Keymer M, Meng L, Bian A, Atassi N, Andrews J, Ennist DL. Jahandideh S, et al. Among authors: ennist dl. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):294-302. doi: 10.1080/21678421.2017.1418003. Epub 2017 Dec 20. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29260584
37 results